-
-
-
Cardiovascular device firms of every shape and size - small caps, medium caps, big caps, early stage, development-stage and commercialization stage - took part in the 24th annual JPMorgan Healthcare Conference at the packed-as-usual Westin St. Francis Hotel early last month. The fact that nearly all of them drew standing-room-only audiences to their respective presentation venues shows the continuing interest the sector holds for the investment community.
-
Doug Braunstein, head of Americas investment banking for JPMorgan Chase, said in delivering his welcoming remarks at the 24th annual JPMorgan Healthcare Conference in San Francisco last month that he couldn't remember a year that had as much "transformational activity" for healthcare and healthcare investors as witnessed in 2005.
-
Clinical trial testing of drug-eluting stent (DES) devices over the remainder of this decade will seek to asses new, more complex uses and outcomes.
-
Cardiovascular therapies often require patients to make very tough choices.
-
Biophan Europe (Castrop-Rauxel, Germany), the European subsidiary of Biophan Technologies (West Henrietta, New York), has reported a series of operational achievements for 2005.
-
ATS Medical (Minneapolis) developer, manufacturer and marketer of cardiac surgery products and services, reported a definitive agreement under which it will acquire all the outstanding shares of privately held 3F Therapeutics (Lake Forest, California) in a stock-for-stock transaction with a potential value with milestones of nearly $58 million.
-
Those involved with the medical diagnostics sector like to refer to how diagnostics - despite accounting for under 5% of hospital costs and less than 2% of total healthcare expenditures - are responsible for between 60% and 70% of healthcare decisions. Ken Buechler, president and chief scientific officer of Biosite (San Diego), expressed the diagnostics development proposition succinctly: "Improving diagnostics will improve healthcare outcomes and save lives."
-
It appears that the saga of who will buy troubled cardiac rhythm management (CRM) firm Guidant (Indianapolis) is finally over, with Johnson & Johnson (J&J; New Brunswick, New Jersey) letting a deadline to best rival suitor Boston Scientific's (Natick, Massachusetts) most recent offer of $80 a share, or about $27.2 billion, expire at midnight on Jan. 25.
